ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,099.96
      1.02%
      US Tech 100
      17,240.00
      1.54%
      Dow Jones
      38,239.66
      0.40%
      Brent Oil
      88.165
      0.02%
      Bitcoin
      63,732.45
      -1.17%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. argenx SE (ARGX)

      7. argenx SE (ARGX) News

      ARGX argenx SE

      372.80
      4.20 (1.14%)
      After Hours
      Last Updated: 18:06:30
      Delayed by 15 minutes
      Company Name Stock Ticker Symbol Market Type
      argenx SE ARGX NASDAQ Depository Receipt
        Price Change Change Percent Stock Price Last Traded
      Upgrade Icon
      4.20 1.14% 372.80 18:06:30
      Open Price Low Price High Price Close Price Prev Close
      370.35 366.72 375.795 372.80 368.60
      more quote information »

      Recent News

      Date Time Source Heading
      4/16/202401:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
      3/27/202402:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
      3/26/202416:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
      3/26/202402:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
      3/08/202406:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      3/07/202416:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
      2/29/202416:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      2/29/202401:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
      2/26/202401:00GLOBEargenx to Present at Upcoming Investor Conferences
      2/22/202401:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
      2/20/202406:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      2/20/202401:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
      1/18/202406:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/18/202401:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
      1/08/202406:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      1/08/202401:00GLOBEargenx Highlights 2024 Strategic Priorities
      1/02/202401:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
      12/20/202312:37DJNArgenx Down Nearly 26%, on Pace for Record Percent Decrease..
      12/20/202306:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      12/20/202301:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
      11/28/202311:16DJNArgenx Down Over 10%, On Track for Largest Percent Decrease..
      11/28/202307:03DJNArgenx Shares Down After Vyvgart Study Misses Primary..
      11/28/202306:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/28/202301:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
      11/17/202306:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/16/202307:40GLOBEargenx Announces European Commission Approval of..
      11/01/202316:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      11/01/202302:00GLOBEargenx Highlights Data Evaluating VYVGART in Neuromuscular..
      10/31/202309:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      10/31/202302:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
      10/24/202301:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
      9/27/202316:42EDGAR2Form S-8 - Securities to be offered to employees in employee..
      9/21/202308:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      9/21/202301:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
      9/15/202301:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
      8/30/202301:00GLOBEargenx to Present at Upcoming Investor Conferences
      7/27/202306:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      7/27/202301:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
      7/24/202316:30GLOBEargenx announces closing of global offering
      7/20/202316:51EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
      7/20/202301:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
      7/19/202317:58GLOBEargenx announces full exercise of underwriters’ option to..
      7/18/202321:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
      7/17/202316:58DJNArgenx Launches $750 Million Global Offering
      7/17/202316:42EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
      7/17/202316:01GLOBEargenx announces launch of proposed global offering
      7/17/202311:59DJNArgenx Up Over 30%, on Track for Record High Close -- Data..
      7/17/202311:04DJNArgenx Shares Hit 52-Week High After Positive Vyvgart..
      7/17/202307:56EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
      7/17/202307:10DJNArgenx, Zai Lab Shares Rise After Positive Trial Results for..

      Your Recent History

      NASDAQ
      ARGX
      argenx
      Delayed Upgrade Clock